51�Թ������ܿƴ�

The Alzheimer's Drug Discovery Foundation (ADDF) will be leading a roundtable, "Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments," at the 2024 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 29th through November 1st in Madrid, Spain.

51�Թ������ܿƴ� recently received a $1.5 million grant from the U.S. Department of Energy to study the effects of radiation exposure and the risk of breast cancer in occupational and medical radiation.

Stranded on a desert island, I could live off nothing but bread, bananas and broccoli. That’s what I say, anyway. My wife scoffs. What about protein? Hmm, beans, I suppose, sticking stubbornly to my B-inspired list. But I’m no nutritionist. And like many people, I’m often confused by the competing and conflicting claims about what we should eat.

The Alzheimer's Drug Discovery Foundation (ADDF) today announced a new investment to develop a first-of-its-kind Biomarker Observatory that will provide a comprehensive overview of the Alzheimer's biomarkers pipeline, including blood tests, brain scans, digital devices, and other tools that can help diagnose and monitor the disease. These efforts will be led by renowned clinical trialist Jeffrey Cummings, MD, ScD, Joy Chambers-Grundy Professor of Brain Science at the School of Integrated Health Sciences at 51�Թ������ܿƴ� with Co-Principal Investigator Feixiong Cheng, PhD, from the Laboratory of Network Medicine at Cleveland Clinic. This Observatory will fill a critical gap by creating the first thorough overview of the biomarker pipeline, serving as a key resource to catalyze progress in drug development.

Today, Global Alzheimer’s Platform Foundation® (GAP) and the 51�Թ������ܿƴ� (51�Թ������ܿƴ�), announced a memorandum of understanding (MOU) regarding a collaboration to accelerate research for neurodegenerative diseases. This includes establishing a state-of-the-art imaging and emerging technology program dedicated to the development and implementation of new and innovative biomarker and diagnostic solutions for central nervous system (CNS) research.

Over the past two years, Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla, both anti-amyloid antibodies, made history as the first real options to slow cognitive decline associated with Alzheimer’s disease. For years, amyloid plaques and tau tangles have been a primary target of Alzheimer’s disease research and drug development, but while affecting these proteins may yield some benefit, the illness continues to progress. Today, multiple therapeutics are in Phase III trials with other targets, suggesting that within the next few years it may become possible to treat Alzheimer’s via multiple pathways.

I love to run—but I detest running uphill. When I hit an incline, my legs burn, I get acid reflux, and I often need to take a break to catch my breath. Jogging over hills is so terrible for me that I exclusively map out flat routes and sign up for races with minimal elevation, if any. As it turns out, there’s a legitimate reason people struggle with hills. Every single one of us has a unique running style, or running fingerprint, as John Mercer, a professor of Kinesiology and Nutrition Sciences at the 51�Թ������ܿƴ�, calls it.

You don’t need to be deep in the fitness world to have run into the idea that cardio “kills” muscle gains—as if every cycling class and or 3-mile run sends a little army of molecules through your body to chomp away at hard-earned muscle tissue. While it’s an entertaining image and a potentially convincing theory, the reality is that it’s not exactly true.

You don’t need to be deep in the fitness world to have run into the idea that cardio “kills” muscle gains—as if every cycling class and or 3-mile run sends a little army of molecules through your body to chomp away at hard-earned muscle tissue. While it’s an entertaining image and a potentially convincing theory, the reality is that it’s not exactly true.

A Radiology Partners affiliate has teamed with a local university to bolster its talent pipeline. Desert Radiology Chief Operating Officer Matt Grimes, MBA, earned his degree in radiography administration from the 51�Թ������ܿƴ�, in 1996. Twenty years later when he joined the practice, one of his top priorities was reinstituting a collaboration allowing 51�Թ������ܿƴ� second-year radiography students to gain experience at DR facilities.

You might think electrolytes are some kind of lab-made superfuel for elite athletes and those who want to be like them. Electrolytes are indeed powerful, and in some circumstances, your body might benefit from a boost. But like comic book heroes with mild-mannered alter egos, they might already be hanging around in your life by another name. And like a movie franchise with one sequel too many, more is not always better.

Not all carbohydrates are created equal. While the complex carbohydrate is  an important part of a healthy, balanced diet—as they help us feel full and offer sustainable energy—refined or simple carbs typically increase blood sugar levels as high glyemic index (GI) foods and add very little nutritional value.